Press release
Leading Element Driving Change in the Glomerulonephritis Market in 2025: Rising Prevalence Of Kidney Disorders Driving The Market Growth Driver
Glomerulonephritis
The growing prevalence of kidney disorders is projected to propel the glomerulonephritis market. Kidney disorders are conditions that affect the kidneys' structure or function, leading to impaired filtration, waste removal, and fluid balance. The rise in kidney disorders is due to factors such as an aging population, increasing chronic disease rates (like diabetes and hypertension), and lifestyle factors. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, which in turn impairs kidney function. For example, in December 2024, the Australian Institute of Health and Welfare reported that chronic kidney disease (CKD) mortality rates rose by 4.2% in 2021 and 6.2% in 2022. In the 2021-22 period, CKD was involved in approximately 2 million hospitalizations, accounting for 18% of all hospital admissions in Australia. Therefore, the growing prevalence of kidney disorders will drive the growth of the glomerulonephritis market.
Get Your Glomerulonephritis Market Report Here:
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report
What growth opportunities are expected to drive the glomerulonephritis market's CAGR through 2034?
The glomerulonephritis market has experienced strong growth, increasing from $11.06 billion in 2024 to $11.64 billion in 2025 at a CAGR of 5.3%. Growth factors include a rising prevalence of kidney disorders, increased cases of infections like post-streptococcal glomerulonephritis, greater investment in R&D, a rise in kidney failure cases, and improved awareness of kidney diseases.
The glomerulonephritis market is expected to grow steadily, reaching $14.14 billion by 2029 at a CAGR of 5.0%. Factors driving this growth include increasing cases of diabetes, an aging population, higher healthcare investments, a growing number of dialysis patients, and a rise in autoimmune diseases. Notable trends include the introduction of new treatments and therapies, advancements in diagnostic technologies, development of novel therapeutics, strategic collaborations between companies, and the adoption of intravenous immunoglobulin therapy.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
What are the emerging trends shaping the future of the glomerulonephritis market?
In the glomerulonephritis market, companies are developing non-immunosuppressive treatments to treat kidney diseases without compromising immune function. One such treatment, FILSPARI (sparsentan), was introduced by Travere Therapeutics Inc., a US-based biopharmaceutical company, in September 2024. The FDA-approved drug is designed to treat IgA nephropathy, a kidney disease, and has shown significant promise in slowing the progression of kidney function decline, offering a non-immunosuppressive option for patients who previously had limited treatments.
Which growth-oriented segments of the glomerulonephritis market are leading the industry's development?
The glomerulonephritis market covered in this report is segmented -
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193
What regions are leading the charge in the glomerulonephritis market?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What companies are at the forefront of innovation in the glomerulonephritis market?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
What Is Covered In The Glomerulonephritis Global Market Report?
•Market Size Forecast: Examine the glomerulonephritis market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the glomerulonephritis market for a structured understanding.
•Key Players Overview: Analyze major players in the glomerulonephritis market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glomerulonephritis market.
•Segment Contributions: Evaluate how different segments drive overall growth in the glomerulonephritis market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glomerulonephritis market.
•Industry Challenges: Identify potential risks and obstacles affecting the glomerulonephritis market.
•Competitive Landscape: Review strategic developments in the glomerulonephritis market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Element Driving Change in the Glomerulonephritis Market in 2025: Rising Prevalence Of Kidney Disorders Driving The Market Growth Driver here
News-ID: 3934870 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Glomerulonephritis
Glomerulonephritis Industry Report 2025-2034: Market Dynamics, Trends, And Forec …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected Glomerulonephritis Market Size During the Forecast Period?
In recent years, the market size of glomerulonephritis has shown appreciable growth. It is predicted to escalate from $11.06 billion in 2024 to $11.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this growth…
Glomerulonephritis Market: An In-Depth Analysis
Glomerulonephritis is a condition affecting the kidneys, specifically the glomeruli, which are small blood vessels responsible for filtering waste from the blood. When these glomeruli become inflamed, it can lead to impaired kidney function. Glomerulonephritis can be caused by infections, autoimmune diseases, or other underlying health conditions. Its significance lies in its potential to cause chronic kidney disease (CKD) or end-stage renal failure if left untreated. With an increasing prevalence…
Glomerulonephritis Treatment Market Size, Share, Industry, Forecast and outlook …
Glomerulonephritis Treatment Market
Glomerulonephritis Treatment Market Poised for Growth, Expected to Reach 5.4% CAGR by 2031
The global Glomerulonephritis Treatment Market is set to exhibit a robust growth trajectory, with a projected Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period from 2024 to 2031.
Glomerulonephritis, also known as Bright's disease, is a progressive kidney ailment characterized by the impairment of glomeruli, the kidney's filtering units responsible for eliminating waste through…
Glomerulonephritis Market to Grasp Outstanding CAGR of 4.70% by 2029
The glomerulonephritis market is expected to witness market growth at a rate of 4.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on glomerulonephritis market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The rise in healthcare sector globally is escalating the growth of glomerulonephritis market.
Get Full Report: https://www.databridgemarketresearch.com/reports/global-glomerulonephritis-market
Glomerulonephritis…
Glomerulonephritis Treatment Market Set for Rapid Growth And Trend, by 2028
Glomerulonephritis Treatment Market: Introduction
Glomerulonephritis, also known as Bright's disease, is a progressive kidney disease that damages the glomeruli—the filtering units of the kidney that create urine as a waste. There are two types of glomerulonephritis, namely acute glomerulonephritis and chronic glomerulonephritis. The acute glomerulonephritis disease develops suddenly and can be caused by infections, such as strep throat. Acute glomerulonephritis disease can also be caused by infection in the throat or…
Glomerulonephritis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Glomerulonephritis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H1 2017, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience…
